Epitalon
Also known as Epithalon, Epithalone, AEDG, Ala-Glu-Asp-Gly, AEDG peptide
A four-amino-acid peptide studied almost only by one Russian network. No trial with a clinical outcome was found; its lifespan data are from animals.
No registered human trial of epitalon was found on ClinicalTrials.gov, and no randomised trial measuring a clinical outcome was found. FDA's July 2026 briefing describes one study, of a melatonin breakdown product in women working night shifts, as "a randomized, placebo-controlled study", while noting it "did not specify blinding" and "did not evaluate sleep outcomes"; the abstract read for this page does not describe randomisation or a placebo, and the full text could not be opened (source). The few reports of it being given to people are uncontrolled, come from the group that developed it, and measure surrogates such as a melatonin breakdown product in urine (source) or a loosely defined effect in an eye disease (source). The human mortality figures that circulate online come from epithalamin, an extract of cattle pineal gland, not from epitalon (source). Every lifespan study found comes from one research network centred in St Petersburg, and no independent replication was found. That is why this page classes it as preclinical only.
What it is
Epitalon, also written epithalon or epithalone, is a synthetic tetrapeptide, a chain of four amino acids: alanine, glutamic acid, aspartic acid and glycine, written AEDG. FDA's substance registry lists it with free ends and no modifications (source). Its formula is C14H22N4O9 and its molecular weight 390.35 (source).
It was designed from the amino acid composition of epithalamin (source). The two are different products. Epithalamin is a mixture of peptides; epitalon is one molecule. The originating group reported in 2017 that AEDG was detected in what it calls the "epiphysis polypeptide complex", a pineal peptide mixture, and that this component determines the mixture's effects (source), a claim no independent confirmation of which was found. PubChem's record lists a CAS number that PubMed attaches to epithalamin among its synonyms; this page uses only 307297-39-8, the number in FDA's registry.
Where the evidence stands
In animals the picture is mixed. In female SHR mice, the one lifespan study that states its group size (54), mean lifespan did not change; only the longest-lived animals lived longer (source). In female rats under standard light, lifespan did not change (source), and in male rats mean lifespan virtually did not change (source). In mice bred to develop breast tumours, a positive 2002 result (source) sits beside a later reanalysis that a 2025 review describes as showing, at some doses, shorter maximum lifespan (source).
Telomeres
Regulatory position
FDA lists epitalon among bulk substances nominated for compounding and then withdrawn, and says it lacks the information to know whether it would harm people (source). An orphan designation for retinitis pigmentosa granted in 2010 is recorded as withdrawn or revoked (source). It is absent from the May 2026 503A categories list (source). It is often described online as approved in Russia; no document establishing that was found.
Epitalon was nonetheless reviewed by FDA's Pharmacy Compounding Advisory Committee on 24 July 2026 for insomnia, after the nominations were withdrawn and FDA continued the evaluation "at its discretion". FDA's briefing for that meeting, which is not a final determination, found "a lack of evidence to support the effectiveness" for insomnia, concluded that "there are no clinical data to support the safety" of either form in humans, and weighed against adding it to the 503A compounding list (source). Press and legal reports, which are second hand, say the committee nonetheless voted to recommend epitalon for the list, by what the trade journal calls a similarly tight margin, without a count; FDA had posted no vote record by 6 November 2026, and a recommendation does not put it on the list (source, source). In October 2026 HHS, FDA's parent department, said it does not intend to act against compounders of epitalon acetate who meet ten listed conditions, while recording that CDER, FDA's drug centre, recommended against listing (source). The notice calls that policy a non-binding draft (source); it is not an approval and it does not add epitalon to the list.
What the research shows
Each statement below is labelled with the strongest kind of study supporting it, and links to that study.
- Human case reportSupportive / Very low confidence
In people with retinitis pigmentosa, a report from the originating group whose abstract describes no control group (PubMed nonetheless indexes it as a controlled clinical trial) described a positive clinical effect in 90% of cases, without stating the number of patients or how the effect was defined.
Khavinson and colleagues reported in 2002 on epitalon in retinitis pigmentosa, an inherited disease of the retina, with a component in Campbell rats and a component in patients. The abstract reports a "positive clinical effect in 90% of the cases". It gives no number of patients, describes no control group and no randomisation, and does not define the endpoint.
One or a few individual cases. Cannot show whether an effect is general.
- No control group is described, so improvement cannot be separated from natural variation or expectation.
- Only the abstract was read. Patient numbers quoted elsewhere come from a secondary review and are not used here.
- Published by the group that developed epitalon.
- Human case reportSupportive / Very low confidence
In middle-aged people, a report from the originating group found 1.7 times higher urinary excretion of a melatonin metabolite after epitalon. This is a surrogate measure, and the record gives no sample size or control group.
Ivko and colleagues (2020, in Russian) sampled urine and white blood cells from middle-aged people and from people with reduced pineal melatonin production. The abstract reports that the peptide increased excretion of 6-sulfatoxymelatonin, a breakdown product of melatonin, "in 1,7 times". A 2007 report by Korkushko and colleagues, covering both epitalon and the pineal extract epithalamin in old rhesus monkeys and elderly people, states only that the preparations restored night-time melatonin release.
One or a few individual cases. Cannot show whether an effect is general.
- Melatonin metabolites and gene expression are surrogates. Neither report measured health, disease or survival.
- Neither abstract states a sample size or describes a control group. FDA's July 2026 briefing, citing the 2021 English version of the Ivko study, describes it as "a randomized, placebo-controlled study" in women aged 40 to 50 working mostly night shifts, notes that it "did not specify blinding" and that it "did not evaluate sleep outcomes" (pp. 26 to 27). That full text could not be opened for this page.
- The 2007 report mixes two substances and two species, and gives no figures.
- Only the abstracts were read.
- Human case reportInsufficient evidence / Very low confidence
The human mortality reductions often attributed to epitalon come from studies of epithalamin, a bovine pineal gland extract, and are not evidence about epitalon.
Studies from the same network report lower mortality in elderly people given epithalamin, in one case together with a thymus extract, thymalin. One abstract reports mortality falling 1.6 to 1.8-fold with epithalamin in 266 elderly people followed for 6 to 8 years; another reports 28% fewer deaths and 2-fold lower cardiovascular mortality over 12 years in elderly people with coronary disease; a third, in 39 treated and 40 control coronary patients, reports lower mortality without figures. None of them gave epitalon. Epithalamin is a mixture; epitalon is one synthetic tetrapeptide.
One or a few individual cases. Cannot show whether an effect is general.
- These figures are about a different substance and are recorded here only so they can be recognised when they appear on other sites.
- All abstracts only, all from the originating network. The first does not describe randomisation or a control group despite being indexed as a randomised trial.
- The 2006 and 2011 coronary cohorts may overlap; this cannot be settled from the abstracts.
- Animal researchMixed / Low confidence
In female outbred SHR mice (54 per group), epitalon did not change mean lifespan; the authors report a 13.3% longer lifespan in the last 10% of survivors and a 12.3% longer maximum lifespan.
Anisimov and colleagues (2003) gave epitalon to female SHR mice. It "did not influence food consumption, body weight or mean life span". The lifespan of the last 10% of survivors rose 13.3% and maximum lifespan 12.3%. It did not change total spontaneous tumour incidence; the authors report 6-fold less leukaemia.
Observed in animals. Animal results frequently fail to replicate in humans.
- The only lifespan study with a stated group size, and mean lifespan was unchanged.
- Maximum lifespan and the last 10% of survivors rest on a handful of animals per group and are statistically fragile.
- No independent replication was found. Only the abstract was read.
- Animal researchMixed / Low confidence
In rats of unreported strain, epitalon did not change lifespan in females under a standard light regimen and virtually did not change mean lifespan in males; under natural and constant light, female maximum lifespan rose by 95 and 24 days.
Vinogradova and colleagues kept female rats under three light regimens. Under standard light epitalon "did not change the life span"; under natural and constant light the authors report longer maximum lifespan, by 95 and 24 days. Under those two regimens the last 10% of females lived 137 and 43 days longer. A second study in male rats reports epitalon "virtually did not change the mean lifespan", and both report fewer spontaneous tumours under some regimens.
Observed in animals. Animal results frequently fail to replicate in humans.
- The rat strain is not given in either record, nor the number of animals.
- Same research network as all other lifespan studies. Only abstracts were read.
- Animal researchContradictory / Very low confidence
In female transgenic FVB/N HER-2/neu mice, a model prone to breast tumours, one report found 13.5% longer mean lifespan (p<0.05) and 13.9% longer maximum lifespan (no p-value given), and a later reanalysis is described as finding, depending on dose, either reduced maximum lifespan or significantly better survival.
Anisimov and colleagues (2002) report that epitalon "prolonged the average and maximum lifetimes of mice by 13.5 (p<0.05) and 13.9%". A 2004 reanalysis using a frailty model, by the same network, gives no outcome figures in its abstract; a 2025 review describes it as finding that, depending on dose, epitalon could "either reduce the maximum lifespan of mice" or "significantly enhance survival rates". In the same model the group reports fewer and smaller tumours, with lung metastases smaller but not fewer in one report and 1.6 times less frequent in another; the two may describe the same experiment.
Observed in animals. Animal results frequently fail to replicate in humans.
- The conflicting result is known only through a secondary review; the reanalysis abstract does not state it.
- The group size is not given. Several tumour papers from this model may report the same experiment.
- Only abstracts of the primary studies were read.
- Animal researchMixed / Very low confidence
In female senescence-accelerated SAMP-1 mice, the last 10% of survivors lived longer with epitalon, and tumour frequency was unchanged.
Anisimov and colleagues (2005) report longer survival of "the 10% of the last survivors among SAMP-1" mice, and that "neither did epitalon affect frequency" of tumours. No figures or group sizes are given in the abstract.
Observed in animals. Animal results frequently fail to replicate in humans.
- Last-survivor measures are fragile. Mean lifespan is not reported in the abstract.
- Same research network. Only the abstract was read.
- Animal researchSupportive / Very low confidence
In Drosophila melanogaster (Canton-S fruit flies), epitalon was reported to increase adult lifespan by 11 to 16%.
Khavinson and colleagues (2000) report that epitalon "increased the lifespan (LS) of imagoes by 11-16%", imagoes being adult flies. The abstract gives no sample size.
Observed in animals. Animal results frequently fail to replicate in humans.
- An insect result says little about mammals.
- No independent replication was found. Only the abstract was read.
- In-vitroSupportive / Low confidence
In cultured human fetal fibroblasts, the originating group reported that epitalon increased telomerase activity and telomere length, and that treated cells made 10 extra divisions beyond controls.
Telomerase is the enzyme that rebuilds telomeres, the protective caps on chromosome ends. Khavinson and colleagues (2003) report higher telomerase catalytic subunit expression, telomerase activity and telomere length in telomerase-negative human fetal fibroblasts. A 2004 follow-up reports that treated cells "made 10 extra divisions (44 passages) in comparison with the control".
Observed in cells or tissue outside a living organism.
- Cells in a dish. No study has measured telomere length in people given epitalon.
- The 2003 abstract gives no figures. Only abstracts were read.
- In-vitroMixed / Very low confidence
In lymphocytes from 11 donors, cultured with epitalon, the originating group found telomere length changed in 7: it increased in 5 and decreased, by 37% and 15%, in the other 2.
Khavinson and colleagues (2019) cultured stimulated white blood cells from 5 young and 6 middle-aged donors. Changes were "found in 7 of 11 individuals", with increases "revealed in 5 cases" and "a significant decrease in telomere length (by 37 and 15%, respectively)" in the other two.
Observed in cells or tissue outside a living organism.
- The effect ran in both directions, so this is not evidence of telomere lengthening.
- Cells were treated in culture; the donors were not given anything. Only the abstract was read.
- In-vitroMixed / Low confidence
An independent 2025 cell study found epitalon raised hTERT expression and lengthened telomeres in human cell lines, including breast cancer lines, where lengthening came through the ALT pathway rather than telomerase.
Al-Dulaimi and colleagues at Brunel University London, unconnected to the originating group, studied two breast cancer lines (21NT and BT474) and normal fibroblasts and mammary epithelial cells. In 21NT cells telomeres lengthened "from 2.4 kb to 4 kb" and hTERT, the telomerase gene, was "upregulated 12-fold", yet telomerase activity did not rise significantly in the cancer lines; instead ALT activity, a telomerase-independent way of lengthening telomeres, rose ten-fold in 21NT. The authors report telomerase upregulation in the normal cells.
Observed in cells or tissue outside a living organism.
- The authors describe it as an in vitro study in 2D cell culture. Their suggestion that epitalon could be used safely in healthy people goes beyond what cell data can show.
- Telomere lengthening in cancer cells is a reason for caution, not reassurance.
- A published correction exists whose content could not be retrieved.
Reported and theoretical risks
- Mechanismunknown
Immunogenicity from aggregation and impurities in compounded products
FDA states that compounded drugs containing epitalon "may pose risk for immunogenicity for certain routes of administration" "due to the potential for aggregation and peptide-related impurities", and that it "lacks sufficient information to know whether the drug would cause harm if administered to humans."
- Mechanismunknown
No systematic human safety data
The research behind this page found no adverse event reports, case reports or pharmacovigilance data for epitalon. A 2025 review of the literature states that information about the peptide's safety is missing. Absence of reports is not evidence of safety when no controlled human trial has been run.
- In-vitrotheoretical
Telomere lengthening in cancer cells
In an independent cell study, epitalon lengthened telomeres in two breast cancer cell lines, partly through the ALT pathway. Whether this happens in a living body is unknown; the originating group's animal studies report fewer or smaller tumours in a breast-tumour mouse model and in rats under some light regimens, and no change in total tumour incidence in SHR and SAMP-1 mice.
Regulatory status
Status differs by country and changes over time. Each entry is dated and sourced.
USFDAunclear
FDA lists epitalon in the table of bulk drug substances nominated for compounding but withdrawn. It states that compounded drugs containing epitalon "may pose risk for immunogenicity for certain routes of administration" "due to the potential for aggregation and peptide-related impurities", and that the agency "lacks sufficient information to know whether the drug would cause harm if administered to humans."
As of 22 April 2026. Source
USFDAnot approved
FDA's orphan drug database records an orphan designation for epitalon for "Treatment of retinitis pigmentosa", designated 2 September 2010, sponsor BioDiem Ltd, with the status "Designated/Designation Withdrawn or Revoked" and "Not FDA Approved for Orphan Indication". An orphan designation is not an approval.
As of 10 October 2026. Source
USFDAunclear
FDA's 503A bulk drug substance categories list updated on 14 May 2026 does not include epitalon in category 1, 2 or 3.
As of 14 May 2026. Source
USFDAnot approved
FDA's briefing document for the July 2026 advisory committee concludes that "a balancing of the criteria weighs against epitalon (free base) or epitalon acetate being placed on that list" and proposes "not adding" them. It finds "a lack of evidence to support the effectiveness" for insomnia, noting that the clinical information concerns melatonin or melatonin metabolite levels and that it "did not identify studies evaluating the use of these substances in patients with insomnia". It concludes "there are no clinical data to support the safety of epitalon (free base) or epitalon acetate when used in humans", and its FAERS search through 8 December 2025 "retrieved no reports". It states that neither form "is a component of an FDA-approved drug". It adds that compounders "generally do not report adverse events to FDA", that FDA "will not issue a final determination" until the advisory committee process is complete, and that the nominations were withdrawn and FDA "is evaluating the substances at its discretion". Read from the full briefing (pp. 1, 8, 9, 26 to 27, 36, 38, 40 to 41).
As of 24 July 2026. Source
USFDAunclear
Epitalon (free base) and epitalon acetate were on the agenda of FDA's Pharmacy Compounding Advisory Committee on 24 July 2026, with the use evaluated stated as "Insomnia". No vote or outcome was found on the meeting page, reopened on 6 November 2026. Epitalon is not listed for the committee's later meeting planned before the end of February 2027.
As of 24 July 2026. Source
USFDA advisory committeeunclear
Second hand: a law firm and a trade journal both report that the committee voted to recommend adding epitalon to the 503A bulks list at its 23-24 July 2026 meeting, against FDA's own proposal. Neither gives the count, or says whether the vote covers the free base, the acetate or both. FDA's meeting page, reopened on 6 November 2026, posts no vote record, though HHS's October 2026 policy states that the committee voted in favour. The vote is advice: it does not place epitalon on the 503A bulks list, which needs FDA to accept it and complete rulemaking.
As of 6 November 2026. Source
USHHSnot approved
HHS's enforcement discretion policy, noticed in the Federal Register on 30 October 2026, says HHS does not intend to act against a state-licensed pharmacy, federal facility or licensed physician compounding epitalon acetate, for subcutaneous or intramuscular injectable dosage forms dispensed in intermittent courses, when ten listed conditions are met, among them a patient-specific prescription and a single active ingredient. It does not approve the substance or add it to the 503A bulks list, and it runs until a final rule addresses the substance. The Federal Register notice calls it a draft, takes comments for two weeks after publication and says it is not binding. HHS records that CDER, FDA's drug centre, recommended against listing; HHS describes the limited controlled human exposure as free of reported side effects, naming no study; FDA's briefing concluded there are no clinical data to support epitalon's safety. The policy makes no finding that the substance works.
As of 2 November 2026. Source
Research and analysis
Sources
- 1. Khavinson V et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinology Letters. 2002. PubMed 12195242
- 2. Ivko OM et al. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Advances in Gerontology (Uspekhi Gerontologii). 2020. PubMed 33280326
- 3. Korkushko OV et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Advances in Gerontology (Uspekhi Gerontologii). 2007. PubMed 17969590
- 4. FDA Briefing Document for Epitalon-Related Bulk Drug Substances (Epitalon (free base) and Epitalon acetate), Pharmacy Compounding Advisory Committee, July 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 5. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. 2003. PubMed 14523363
- 6. Korkushko OV et al. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bulletin of Experimental Biology and Medicine. 2006. PubMed 17426848
- 7. Korkushko OV et al. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bulletin of Experimental Biology and Medicine. 2011. PubMed 22451889
- 8. Anisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003. PubMed 14501183
- 9. Vinogradova IA et al. Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes. Bulletin of Experimental Biology and Medicine. 2007. PubMed 18856211
- 10. Vinogradova IA et al. Geroprotective effect of ala-glu-asp-gly peptide in male rats exposed to different illumination regimens. Bulletin of Experimental Biology and Medicine. 2008. PubMed 19110597
- 11. Anisimov VN et al. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. Bulletin of Experimental Biology and Medicine. 2002. PubMed 12459848
- 12. Semenchenko GV, Anisimov VN, Yashin AI. Stressors and antistressors: how do they influence life span in HER-2/neu transgenic mice?. Experimental Gerontology. 2004. PubMed 15501020
- 13. Araj SK et al. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. 2025. PubMed 40141333(open access)
- 14. Anisimov VN et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. International Journal of Cancer. 2002. PubMed 12209581
- 15. Anisimov VN et al. Effect of epitalon and melatonin on life span and spontaneous carcinogenesis in senescence accelerated mice (SAM). Voprosy Onkologii. 2005. PubMed 15909815
- 16. Khavinson VK et al. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development. 2000. PubMed 11087911
- 17. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003. PubMed 12937682
- 18. Khavinson VKh et al. Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine. 2004. PubMed 15455129
- 19. Khavinson VK et al. Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes. Bulletin of Experimental Biology and Medicine. 2019. PubMed 31761987
- 20. Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. PubMed 40908429(open access)
- 21. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. View source(open access)
- 22. Search Orphan Drug Designations and Approvals: Epitalon, treatment of retinitis pigmentosa. U.S. Food and Drug Administration. 2010. View source(open access)
- 23. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 24. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. 2026. View source(open access)
- 25. Crossan SS, Watkins S. Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. Holland & Knight Alert. 2026. View source(open access)
- 26. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. U.S. Department of Health and Human Services. 2026. View source(open access)